Comparison of toxin and spore production in clinically relevant strains of Clostridium difficile

Microbiology

Volumn 157, Issue 5, 2011, Pages 1343-1353

  Vohra, Prerna ^a   Poxton, Ian R ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TOXIN;

ARTICLE; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIAL VIRULENCE; CLOSTRIDIUM DIFFICILE; CONTROLLED STUDY; GENOTYPE; GROWTH RATE; IN VITRO STUDY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RIBOTYPING; SPOROGENESIS;

BACTERIAL PROTEINS; BACTERIAL TOXINS; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; SPORES, BACTERIAL;

CLOSTRIDIUM DIFFICILE;

EID: 79955752437     PISSN: 13500872     EISSN: None     Source Type: Journal    
DOI: 10.1099/mic.0.046243-0     Document Type: Article

References (50)

1. Akerlund, T., Svenungsson, B., Lagergren, A. & Burman, L. G. (2006). Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 44, 353-358.
2. Akerlund, T., Persson, I., Unemo, M., Norén, T., Svenungsson, B., Wullt, M. & Burman, L. G. (2008). Increased sporulation rate of epidemic Clostridium difficile type 027/NAP1. J Clin Microbiol 46, 1530-1533.
3. Aktories, K., Schmidt, G. & Just, I. (2000). Rho GTPases as targets of bacterial protein toxins. Biol Chem 381, 421-426.
4. Arvand, M., Hauri, A. M., Zaiss, N. H., Witte, W. & Bettge-Weller, G. (2009). Clostridium difficile ribotypes 001, 017, and 027 are associated with lethal C. difficile infection in Hesse, Germany. Euro Surveill 14, 1-4.
5. Bartlett, J. G., Moon, N., Chang, T. W., Taylor, N. & Onderdonk, A. B. (1978). Role of Clostridium difficile in antibiotic-associated pseudo- membranous colitis. Gastroenterology 75, 778-782.
6. Brown, R., Collee, J. & Poxton, I. (1996). Bacteroides, Fusobacterium and other Gram-negative anaerobic rods; anaerobic cocci; identification of anaerobes. In Mackie and McCartney Practical Medical Microbiology. Edited by J. Collee, A. Fraser, B. Marmion & A. Simmons. London: Churchill Livingstone.
7. Curry, S. R., Marsh, J. W., Muto, C. A., O'Leary, M. M., Pasculle, A. W. & Harrison, L. H. (2007). tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol 45, 215-221.
8. Dineen, S. S., Villapakkam, A. C., Nordman, J. T. & Sonenshein, A. L. (2007). Repression of Clostridium difficile toxin gene expression by CodY. Mol Microbiol 66, 206-219.
9. Drudy, D., Harnedy, N., Fanning, S., Hannan, M. & Kyne, L. (2007). Emergence and control of fluoroquinolone-resistant, toxin A- negative, toxin B-positive Clostridium difficile. Infect Control Hosp Epidemiol 28, 932-940.
10. Dupuy, B. & Sonenshein, A. L. (1998). Regulated transcription of Clostridium difficile toxin genes. Mol Microbiol 27, 107-120.
11. Dupuy, B., Govind, R., Antunes, A. & Matamouros, S. (2008). Clostridium difficile toxin synthesis is negatively regulated by TcdC. J Med Microbiol 57, 685-689.
12. Freeman, J., Baines, S. D., Saxton, K. & Wilcox, M. H. (2007). Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 60, 83-91.
13. George, R. H., Symonds, J. M., Dimock, F., Brown, J. D., Arabi, Y., Shinagawa, N., Keighley, M. R., Alexander-Williams, J. & Burdon, D. W. (1978). Identification of Clostridium difficile as a cause of pseudomembranous colitis. BMJ 1, 695.
14. Govind, R., Vediyappan, G., Rolfe, R. D. & Fralick, J. A. (2006). Evidence that Clostridium difficile TcdC is a membrane-associated protein. J Bacteriol 188, 3716-3720.
15. Health Protection Scotland (2008). Annual report on the surveillance of Clostridium difficile associated disease (CDAD) in Scotland, October 2006-September 2007. HPS Weekly Report 42, 3-9. http:// www.documents.hps.scot.nhs.uk/hai/sshaip/publications/cdad/2007-12-20-ar-cdad.pdf
16. Health Protection Scotland (2010). Quarterly report on the surveillance of Clostridium difficile infection (CDI) in Scotland, January 2010-March 2010. HPS Weekly Report 27, 261-269. http://www.documents.hps.scot.nhs.uk/ewr/pdf2010/1027.pdf
17. Hundsberger, T., Braun, V., Weidmann, M., Leukel, P., Sauerborn, M. & von Eichel-Streiber, C. (1997). Transcription analysis of the genes tcdA-E of the pathogenicity locus of Clostridium difficile. Eur J Biochem 244,735-742.
18. Jump, R. L. P., Pultz, M. J. & Donskey, C. J. (2007). Vegetative Clostridium difficile survives in room air, on moist surfaces and in gastric contents with reduced acidity: a potential mechanism to explain the association between proton pump inhibitors and C. difficile-associated diarrhea? Antimicrob Agents Chemother 51, 2883- 2887.
19. Kamiya, S., Ogura, H., Meng, X. Q. & Nakamura, S. (1992). Correlation between cytotoxin production and sporulation in Clostri- dium difficile. J Med Microbiol 37, 206-210.
20. Karlsson, S., Burman, L. G. & Akerlund, T. (1999). Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids. Microbiology 145, 1683-1693.
21. Karlsson, S., Burman, L. G. & Akerlund, T. (2008). Induction of toxins in Clostridium difficile is associated with dramatic changes of its metabolism. Microbiology 154, 3430-3436.
22. Krivan, H. C., Clark, G. F., Smith, D. F. & Wilkins, T. D. (1986). Cell surface binding site for Clostridium difficile enterotoxin: evidence for a glycoconjugate containing the sequence Gal alpha 1-3Gal beta 1- 4GlcNAc. Infect Immun 53, 573-581.
23. Kuehne, S. A., Cartman, S. T., Heap, J. T., Kelly, M. L., Cockayne, A. & Minton, N. P. (2010). The role of toxin A and toxin B in Clostridium difficile infection. Nature 467, 711-713.
24. Kuijper, E. J., Coignard, B., Brazier, J. S., Suetens, C., Drudy, D., Wiuff, C., Pituch, H., Reichert, P., Schneider, F. & other authors (2007). Update of Clostridium difficile-associated disease due to PCR ribotype 027 in Europe. Euro Surveill 12, E1-E2.
25. Larson, H. E., Price, A. B., Honour, P. & Borriello, S. P. (1978). Clostridium difficile and the aetiology of pseudomembranous colitis. Lancet 311, 1063-1066.
26. Loo, V. G., Poirier, L., Miller, M. A., Oughton, M., Libman, M. D., Michaud, S., Bourgault, A. M., Nguyen, T., Frenette, C. & other authors (2005). A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353, 2442-2449.
27. Lyerly, D. M., Saum, K. E., MacDonald, D. K. & Wilkins, T. D. (1985). Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47, 349-352.
28. Lyras, D., O'Connor, J. R., Howarth, P. M., Sambol, S. P., Carter, G. P., Phumoonna, T., Poon, R., Adams, V., Vedantam, G. & other authors (2009). Toxin B is essential for virulence of Clostridium difficile. Nature 458, 1176-1179.
29. MacCannell, D. R., Louie, T. J., Gregson, D. B., Laverdiere, M., Labbe, A.-C., Laing, F. & Henwick, S. (2006). Molecular analysis of Clostridium difficile PCR ribotype 027 isolates from Eastern and Western Canada. J Clin Microbiol 44, 2147-2152.
30. Matamouros, S., England, P. & Dupuy, B. (2007). Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 64, 1274-1288.
31. McFarland, L. V., Beneda, H. W., Clarridge, J. E. & Raugi, G. J. (2007). Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 35, 237- 253.
32. Merrigan, M., Venugopal, A., Mallozzi, M., Roxas, B., Viswanathan, V. K., Johnson, S., Gerding, D. N. & Vedantam, G. (2010). Human hypervirulent Clostridium difficile strains exhibit increased sporulation as well as robust toxin production. J Bacteriol 192, 4904- 4911.
33. Mutlu, E., Wroe, A. J., Sanchez-Hurtado, K., Brazier, J. S. & Poxton, I. R. (2007). Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland. J Med Microbiol 56, 921- 929.
34. Pe ́pin, J., Valiquette, L., Alary, M.-E., Villemure, P., Pelletier, A., Forget, K., Pe ́pin, K. & Chouinard, D. (2004). Clostridium difficile- associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171, 466-472.
35. Pe ́pin, J., Valiquette, L. & Cossette, B. (2005). Mortality attributable to nosocomial Clostridium difficile-associated disease during an epidemic caused by a hypervirulent strain in Quebec. CMAJ 173, 1037-1042.
36. Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45.
37. Riggs, M. M., Sethi, A. K., Zabarsky, T. F., Eckstein, E. C., Jump, R. L. P. & Donskey, C. J. (2007). Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis 45, 992-998.
38. Rozen, S. & Skaletsky, H. (2000). Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132, 365-386.
39. Smith, A. (2005). Outbreak of Clostridium difficile infection in an English hospital linked to hypertoxin-producing strains in Canada and the US. Euro Surveill 10, E050630, 2. http://www.eurosurveillance. org/images/dynamic/EQ/v05n03/v05n03.pdf
40. Spigaglia, P. & Mastrantonio, P. (2002). Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40, 3470-3475.
41. Sundram, F., Guyot, A., Carboo, I., Green, S., Lilaonitkul, M. & Scourfield, A. (2009). Clostridium difficile ribotypes 027 and 106: clinical outcomes and risk factors. J Hosp Infect 72, 111-118.
42. Sutton, P. A., Li, S., Webb, J., Solomon, K., Brazier, J. & Mahida, Y. R. (2008). Essential role of toxin A in C. difficile 027 and reference strain supernatant-mediated disruption of Caco-2 intestinal epithelial barrier function. Clin Exp Immunol 153, 439-447.
43. Tan, K. S., Wee, B. Y. & Song, K. P. (2001). Evidence for holin function of tcdE gene in the pathogenicity of Clostridium difficile. J Med Microbiol 50, 613-619.
44. Taori, S. K., Hall, V. & Poxton, I. (2009). Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004. J Med Microbiol 59, 338-344.
45. Tucker, K. D. & Wilkins, T. D. (1991). Toxin A of Clostridium difficile binds to the human carbohydrate antigens I, X, and Y. Infect Immun 59,73-78.
46. Underwood, S., Guan, S., Vijayasubhash, V., Baines, S. D., Graham, L., Lewis, R. J., Wilcox, M. H. & Stephenson, K. (2009). Characterization of Toxin and spore production in Clostridium difficile the sporulation initiation pathway of Clostridium difficile and its role in toxin production. J Bacteriol 191, 7296-7305.
47. Vohra, P. & Poxton, I. R. (2010). Characterisation of Clostridium difficile ribotype 027 strains in Scotland. Poster no. SP-4, presented at: Anaerobe 2010, The 10th Biennial Congress of the Anaerobe Society of the Americas, July 7-9, Philadelphia, PA, USA.
48. Warny, M., Pepin, J., Fang, A., Killgore, G., Thompson, A., Brazier, J., Frost, E. & McDonald, L. C. (2005). Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366, 1079-1084.
49. Wilson, K. H. (1983). Efficiency of various bile salt preparations for stimulation of Clostridium difficile spore germination. J Clin Microbiol 18,1017-1019.
50. Wüst, J., Sullivan, N. M., Hardegger, U. & Wilkins, T. D. (1982). Investigation of an outbreak of antibiotic-associated colitis by various typing methods. J Clin Microbiol 16, 1096-1101.